echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Concerned about the rare disease "true red blood cell hypertrophy" :P TG-300 approved by FDA orphan drug

    Concerned about the rare disease "true red blood cell hypertrophy" :P TG-300 approved by FDA orphan drug

    • Last Update: 2020-07-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    True erythropoietin (polycythemia vera, PV) is a bone marrow proliferation tumor, a group of malignant tumors derived from hematopoieticstem cells, characterized by the proliferation of bone marrow cell cloning with different morphological maturityPv differs from other MPNs in the increase dissocyt and is associated with an increased risk ofthrombosisembolism, leukemia conversion, and/or bone marrow fibrosisThe U.SFood and Drug Administration,
    Administration of(
    FDA) has awarded PTG-300 an orphan drug designation for PV, The Pharmaceuticals announced todayPTG-300 is a synthetic peptide that is currently being clinically developedTrue recently published the preliminary results of Phase II clinical trials in patients with true red blood cell growthSamuel Saks, Chief Medical Officer, said: "The FDA's certification of orphan medicines by Thein is an important milestonePatients with true erythrocytic hyperemia face a high disease burden, and PTG-300 has shown good safety in the treatment of true erythrocyte disease with novel therapeutic mechanisms."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.